Novartis AG (NVS)
| Market Cap | 208.25B |
| Revenue (ttm) | 49.92B |
| Net Income (ttm) | 15.25B |
| Shares Out | 1.96B |
| EPS (ttm) | 7.38 |
| PE Ratio | 24.20 |
| Forward PE | 13.25 |
| Dividend | $3.78 (3.55%) |
| Ex-Dividend Date | Mar 7, 2024 |
| Volume | 1,073,090 |
| Open | 106.32 |
| Previous Close | 106.54 |
| Day's Range | 105.90 - 106.68 |
| 52-Week Range | 92.19 - 108.78 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | 115.00 (+8.04%) |
| Earnings Date | Jul 16, 2024 |
About NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn ... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $115.0, which is an increase of 8.04% from the latest price.
News
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights. Pending re...
Novartis and others face Italy antitrust probe over eye drug
Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis , for having potentially restricted competition in the sale of a drug for...
Novartis CEO: Our leukemia drug Scemblix is a potential $3 billion plus medicine
Vas Narasimhan, Novartis CEO, joins 'Squawk on the Street' to discuss the company's positive Leukemia drug results, the review timeline for Scemblix, and insights into Novartis' breast cancer drug.
Novartis leukemia drug more effective than older treatments in trial
Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care drugs...
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Basel, May 31, 2024 – Novartis today presents positive results from the pivotal Phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology (ASCO) meeting. ...
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
Basel, May 31, 2024 – Novartis today announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in chronic spontane...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor a...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical ...
This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
Targeted radiopharmaceuticals has caught the eye of big pharma. The therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
Basel, 16 May 2024 – Today, Novartis BidCo AG, an (indirect) wholly owned subsidiary of Novartis AG, announced the result of its voluntary public takeover offer (the “Offer”) for the shares of MorphoS...
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
Basel, May 15, 2024 – Novartis will present data from more than 60 abstracts, including investigator-initiated trials at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the Eu...
Trade Tracker: The Committee shares some of their buys and sells
The Investment Committee discussestheir latest portfolio moves.
Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer
WAYNE, Pa.--(BUSINESS WIRE)-- #CLI--Cagent Vascular announced today that Brian Walsh has been named Chief Executive Officer by the Cagent Vascular Board of Directors. He has served as Chairman of the ...
Novartis to buy radiology specialist Mariana Oncology for $1 billion
Novartis has entered an agreement to acquire US radiopharmaceutical company Mariana Oncology for $1 billion, the Swiss drug manufacturer said on Thursday.
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer
WATERTOWN, Mass.--(BUSINESS WIRE)--Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it wil...
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
KAWASAKI, Japan--(BUSINESS WIRE)--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced...
Morphosys says Novartis takeover progressing as planned for H1 2024
Morphosys said its takeover by Novartis was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT New...
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies
Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem® (artemether-lum...
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the tr...
Novartis CEO: Here's why we boosted our full-year guidance
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.
Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb
American depositary receipts (ADRs) of Novartis (NVS) rose in intraday trading Tuesday as the Swiss-based pharmaceutical firm reported better-than-expected first-quarter results and boosted its guidan...
Novartis CEO: Broadly Positive About Business Momentum
Novartis CEO Vas Narasimhan said the company saw a very good performance across both established medicines and recent drug launches. "While there was a small contribution from generics getting pushed ...
Novartis shares jump as drugmaker boosts outlook
Novartis shares rallied on Tuesday as the Swiss drugmaker raised its outlook for the year after seeing strong demand for heart and psoriasis drugs.
Shares of Novartis climb 4.8% on raised guidance, better-than-expected results
Shares of Swiss drugmaker Novartis climbed 4.8% in early deals Tuesday after it raised its full-year guidance following better-than-expected first-quarter results.